Report of Foreign Issuer (6-k)
10/01/2017 6:19pm
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending
10 January
2017
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline
plc (the
'
Company
')
Transaction
notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dr M M Slaoui
|
b)
|
Position/status
|
Chairman, Global Vaccines
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial
instrument
|
GlaxoSmithKline plc American Depositary Shares
('ADSs')
ISIN:
US37733W1053
|
b)
|
Nature of
the
transaction
|
An increase of 29 ADSs following the notional allocation of ADSs on
9 January 2017, at a price of $39.43 per ADS, as a result of the
revaluation of the cash element of the notional investment held
within the GSK 401(K) plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
$39.43
|
29
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2017-01-09
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely a
ssociated with them ('PCA')
|
a)
|
Name
|
Dr K Slaoui
|
b)
|
Position/status
|
PCA of Dr M M Slaoui (Chairman, Global Vaccines)
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial
instrument
|
GlaxoSmithKline plc American Depositary Shares
('ADSs')
ISIN:
US37733W1053
|
b)
|
Nature of
the
transaction
|
An increase of 10 ADSs following the notional allocation of ADSs on
9 January 2017, at a price of $39.43 per ADS, as a result of the
revaluation of the cash element of the notional investment held
within the GSK 401(K) plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
$39.43
|
10
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2017-01-09
|
f)
|
Place
of the transaction
|
n/a
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: January
10, 2017
|
|
|
|
|
By: VICTORIA
WHYTE--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|